6 April 2021 | 08:01am
StockMarketWire.com - Security company G4S has completed its £3.8 billion sale to Allied Universal after meeting all of the required offer conditions, including the required antitrust and regulatory approvals. This acquisition creates a world leading integrated security company, providing an unrivalled breadth of capability for customers and new opportunities for the company s teams around the world, Allied said.
Following the completion, G4S will cease trading on the London Stock Exchange and become a private company. It is anticipated that the cancellation of the listing of G4S Shares on the Official List and trading of G4S Shares on the London Stock Exchange s main market for listed securities will take effect no earlier than 5 May 2021, it added.
8 March 2021 | 08:10am
StockMarketWire.com - Security G4S said GardaWorld had received more time to gather the G4S shareholder votes needed to meet a condition to takeover the company following its increased 235 pence takeover offer tabled last month, which was rejected the company.
GardaWorld now had until 1.00 p.m. (London time) 16 March 2021 to satisfy the acceptance condition.
On 23 February 2021, GardaWorld declared its final 235 pence a share offer for G4S, but the offer was rejected in favour of a rival bid from Allied Universal.
G4S had previously said its £3.8 billion takeover by Allied Universal is set for a positive conclusion.
22 February 2021 | 08:36am
StockMarketWire.com - UK stocks opened lower on Monday as rising US bond yields and inflation fears tempered Covid vaccine optimism.
At 0824, the benchmark FTSE 100 index was down 56.45 points, or 0.9%, at 6,567.57.
Security group G4S slumped 9.7% to 242.8p after private equity firm GardaWorld said it wouldn t raise its 235p offer for the company, cooling hopes of a bidding war.
G4S had rejected GardaWorld s offer in favour of 245p bid from Allied Universal.
Pharmaceutical giant AstraZeneca added 0.2% to £72.39 even after it said it was withdrawing a bladder cancer drug in the US after it failed to meet post-marketing requirements in a clinical study.